All Photos(1)

Documents

COA/COQ

444290

MMP Inhibitor V

Name: MMP Inhibitor V
Brand: MM

The MMP Inhibitor V, also referenced under CAS 223472-31-9, controls the biological activity of MMP. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Synonym(s):

MMP Inhibitor V, (2S,4S)-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide, ONO-4817

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₈N₂O₆

CAS Number:

223472-31-9

Molecular Weight:

416.47

UNSPSC Code:

12352200

NACRES:

NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
protect from light

color

off-white

solubility

ethanol: 15 mg/mL
DMSO: 30 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1

InChI key

HDWWQELUBWGQGA-WMZOPIPTSA-N

General description

An orally active non-peptidyl hydroxamate compound that acts as an effective broad-spectrum inhibitor against MMP-2, -3, -8, -9, -12, -13 (K_i = 0.73, 42, 1.1, 2.1, 0.45, and 1.1 nM, respectively), but not MMP-1 (IC₅₀ = 1.6 µM), MMP-7 (K_i = 2.5 µM), or other serine proteases (no activity against chymotrypsin or plasmin at 100 µM). Widely used in studying MMP-mediated diseases development in vivo. Also reported to block P-LAP secretase activity (≥70% inhibition of P-LAP shedding at 10 µM) that is otherwise not inhibited by TIMP-1/2 in CHO cell cultures in vitro.

An orally active non-peptidyl hydroxamate compound that acts as an effective broad-spectrum inhibitor against MMP-2/3/8/9/12/13 (K_i = 0.73, 42, 1.1, 2.1, 0.45, and 1.1 nM, respectively), but not MMP-1 (IC₅₀ = 1.6 µM), MMP-7 (K_i = 2.5 µM), or other serine proteases (no activity against chymotrypsin or plasmin at 100 µM). Widely used in studying MMP-mediated diseases development in vivo. Also reported to block P-LAP secretase activity (≥70% inhibition of P-LAP shedding at 10 µM) that is otherwise not inhibited by TIMP-1/2 in CHO cell cultures in vitro.

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Other Notes

Okamoto, Y., et al. 2007. Int. Heart J.48, 369.
Ito, N., et al. 2004. Biochem. Biophys. Res. Commun.314, 1008.
Shiraga, M., et al. 2002. Cancer Res.62, 5967.
Mori, T., et al. 2001. Exp. Biol. Med.226, 429.
Yamada, A., et al. 2000. Inflamm. Res.49, 144.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.

Søren B van Witteloostuijn et al.

Journal of peptide science : an official publication of the European Peptide Society, 23(12), 845-854 (2017-10-24)

Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight-lowering effects of bariatric surgery involve stimulated secretion of appetite-regulating gut hormones, including glucagon-like

Phosphate-induced activation of VEGFR2 leads to caspase-9-mediated apoptosis of hypertrophic chondrocytes.

Prem Swaroop Yadav et al.

iScience, 26(9), 107548-107548 (2023-08-28)

Low circulating phosphate (Pi) leads to rickets, characterized by expansion of the hypertrophic chondrocytes (HCs) in the growth plate due to impaired HC apoptosis. Studies in HCs demonstrate that Pi activates the Raf/MEK/ERK1/2 and mitochondrial apoptotic pathways. To determine how